Latest Funding And Capital News

Spacetalk Ltd has raised $4.05 million through a combination of a conditional placement and convertible notes to accelerate its geographic expansion and app development, alongside appointing a seasoned director to its board.

Felix Group Holdings has successfully closed its Share Purchase Plan, raising an additional A$0.5 million following a substantial A$16 million institutional placement. The funds will support the company’s strategic acquisition of Nexvia and further platform development.

Australian Unity Investment Real Estate Limited has terminated the sale contract for 150 Charlotte Street in Brisbane after the purchaser failed to complete settlement, retaining a $4.8375 million deposit and planning to re-market the property.

Mesoblast has entered agreements to issue up to US$50 million in convertible notes, aiming to strengthen its capital base and support pipeline growth, pending shareholder approval.

RLF AgTech has completed a $4.5 million placement by issuing over 90 million new shares, bolstering its capacity to advance sustainable crop nutrition solutions across Australia and Asia.

Genmin Limited has increased insider loans by A$0.5 million, reinforcing funding for its flagship Baniaka iron ore project in Gabon as it targets production in late 2026.

Acorn Capital Investment Fund Limited reported a robust FY25 with a $9.67 million profit after tax, a significant leap from $1.77 million the prior year, while delivering a 15.1% portfolio return that outperformed its benchmark.

Dexus has announced its 18.0 cents per security distribution for the first half of 2025, alongside robust full-year results that highlight a resilient portfolio and disciplined capital management. The company signals confidence with a steady outlook despite ongoing economic uncertainty.

Blue Energy Limited has successfully raised $3.2 million through a two-tranche placement, complemented by a proposed $250,000 share purchase plan, to fund drilling and pipeline development in Queensland’s North Bowen Basin.

Staude Capital Global Value Fund Limited has announced a fully franked ordinary dividend of AUD 0.033 per share for the half-year ending June 2025, accompanied by a dividend reinvestment plan offering a 2.5% discount.

Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.

Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.